Regentis Appoints Ex-CartiHeal Leader to Propel GelrinC FDA Trial
Regentis Biomaterials appointed Dr. Galit Reske as Chief Medical Officer, leveraging her leadership on Agili-C’s FDA approval and CartiHeal’s $330 million acquisition. She will guide clinical development and regulatory strategy for GelrinC®, now over 50% enrolled in its pivotal U.S. FDA study, and support planned European launches.
1. Appointment of Chief Medical Officer
Regentis Biomaterials has named Dr. Galit Reske as Chief Medical Officer. Reske brings over nine years of experience in clinical development and regulatory affairs, most recently serving as Director of Clinical Operations at CartiHeal.
2. Proven Cartilage Repair Track Record
At CartiHeal, Reske led the IDE Pivotal Study for Agili-C across more than 30 sites in the U.S., Europe and Israel, secured FDA approval in 2022, and contributed to the company’s acquisition by Smith+Nephew for $330 million in 2023.
3. Strategic Role in GelrinC Advancement
Dr. Reske will direct clinical and regulatory strategy for GelrinC®, a resorbable hydrogel implant treating knee cartilage defects, which is now over 50% enrolled in its pivotal U.S. FDA trial. She will also support planned marketing and sales introductions in Europe and lead conference presentations.